Table 3.
Multivariate survival analysis in ovarian cancer patients
| Variable | Progression‐free survival | Overall survival | |||
|---|---|---|---|---|---|
| HR of progression (95% CI) | P | HR of death (95% CI) | P | ||
| Age | <50 y ≥ | 1.46 (0.86‐2.47) | 0.162 | 2.26 (1.29‐3.95) | 0.004 |
| FIGO stage | I/II vs III/IV | 2.68 (1.33‐5.42) | 0.006 | 1.33 (0.75‐2.33) | 0.327 |
| Tumor grade | 1/2 vs 3 | 1.21 (0.79‐1.84) | 0.378 | 1.39 (0.94‐2.05) | 0.102 |
| Residual disease after surgery | No vs yes | 2.92 (1.71‐4.98) | <0.001 | 3.02 (1.96‐5.24) | <0.001 |
| Histology | HGSOC vs others | 1.03 (0.62‐1.68) | 0.922 | 0.86 (0.54‐1.37) | 0.519 |
| SPATA2 mRNA expression | Low vs high (< or > optimal cut‐off) | 1.55 (1.00‐2.40) | 0.048 | 2.13 (1.41‐3.24) | <0.001 |
Bold values have a significance level of P < 0.05.
The optimal cut‐off points for SPATA2 were calculated by Youden's index. The significance level (P) was determined by Cox regression.
CI, confidence interval; FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; HGSOC, high grade serous ovarian cancer; HR, hazard ratio; n.r., not reached.